• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于糖尿病治疗的 TGR5 激动剂:专利审查和临床进展(2012 年至今)。

TGR5 agonists for diabetes treatment: a patent review and clinical advancements (2012-present).

机构信息

Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India.

Department of Pharmaceutical Chemistry, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, Maharashtra, India.

出版信息

Expert Opin Ther Pat. 2022 Feb;32(2):191-209. doi: 10.1080/13543776.2022.1994551. Epub 2021 Dec 22.

DOI:10.1080/13543776.2022.1994551
PMID:34652989
Abstract

INTRODUCTION

A cell surface bile acid receptor TGR5 is expressed in various tissues, including the liver, kidney, intestine, and adrenal glands, causing its effect in each tissue to differ. A major role for TGR5 is to maintain blood sugar levels and increase in energy expenditure. These benefits make it a potential candidate for the treatment of type 2 diabetes, obesity, and other metabolic diseases.

AREA COVERED

This paper highlights recent advances in the development of potent steroidal and non-steroidal TGR5 agonists and the peer-reviewed scientific articles that have led to understanding the structure-activity relationship for TGR5 agonists (2012-2020). The review also discusses the clinical progress made by some TGR5 agonists over the past eight years.

EXPERT OPINION

In preclinical studies, TGR5 has been found to play a crucial role in GLP-1 secretion and has shown promise for weight loss, anti-diabetic outcomes etc. Semi synthetic and synthetic derivatives can be considered a potential avenue for discovering novel TGR5 agonists. Currently, few TGR5 agonists have reached the clinical trial stage, and, likely, soon novel TGR5 modulator will be discovered with fewer adverse effects. In silico studies can also be performed with various heterocyclic scaffolds to discover selective and safe TGR5 agonists.

摘要

简介

一种细胞表面胆汁酸受体 TGR5 表达于多种组织中,包括肝脏、肾脏、肠道和肾上腺,这导致其在每种组织中的作用不同。TGR5 的主要作用是维持血糖水平并增加能量消耗。这些益处使其成为治疗 2 型糖尿病、肥胖症和其他代谢疾病的潜在候选药物。

涵盖领域

本文重点介绍了近年来强效甾体和非甾体 TGR5 激动剂的开发进展,以及导致理解 TGR5 激动剂结构-活性关系的同行评议科学文章(2012-2020 年)。该综述还讨论了过去八年中一些 TGR5 激动剂在临床方面取得的进展。

专家意见

在临床前研究中,TGR5 被发现在 GLP-1 分泌中发挥着关键作用,并且在减肥、抗糖尿病等方面显示出了潜力。半合成和合成衍生物可以被认为是发现新型 TGR5 激动剂的潜在途径。目前,少数 TGR5 激动剂已经进入临床试验阶段,很可能很快就会发现具有较少副作用的新型 TGR5 调节剂。还可以通过各种杂环支架进行计算机研究,以发现选择性和安全性 TGR5 激动剂。

相似文献

1
TGR5 agonists for diabetes treatment: a patent review and clinical advancements (2012-present).用于糖尿病治疗的 TGR5 激动剂:专利审查和临床进展(2012 年至今)。
Expert Opin Ther Pat. 2022 Feb;32(2):191-209. doi: 10.1080/13543776.2022.1994551. Epub 2021 Dec 22.
2
Clinical relevance of the bile acid receptor TGR5 in metabolism.TGR5 胆汁酸受体在代谢中的临床相关性。
Lancet Diabetes Endocrinol. 2017 Mar;5(3):224-233. doi: 10.1016/S2213-8587(16)30155-3. Epub 2016 Sep 14.
3
Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism.法尼酯X受体诱导武田G蛋白偶联受体5相互作用以调节胆汁酸合成和肝脏代谢。
J Biol Chem. 2017 Jun 30;292(26):11055-11069. doi: 10.1074/jbc.M117.784322. Epub 2017 May 6.
4
Patented TGR5 modulators: a review (2006 - present).专利 TGR5 调节剂:综述(2006 年至今)。
Expert Opin Ther Pat. 2012 Dec;22(12):1399-414. doi: 10.1517/13543776.2012.733000. Epub 2012 Oct 6.
5
GPR120 agonists for the treatment of diabetes: a patent review (2014 present).GPR120 激动剂治疗糖尿病:专利研究综述(2014 年至今)。
Expert Opin Ther Pat. 2020 Oct;30(10):729-742. doi: 10.1080/13543776.2020.1811852. Epub 2020 Aug 30.
6
Update on the development of TGR5 agonists for human diseases.TGR5 激动剂在人类疾病中的研究进展。
Eur J Med Chem. 2024 May 5;271:116462. doi: 10.1016/j.ejmech.2024.116462. Epub 2024 Apr 28.
7
Activation of Transmembrane Bile Acid Receptor TGR5 Modulates Pancreatic Islet α Cells to Promote Glucose Homeostasis.跨膜胆汁酸受体TGR5的激活调节胰岛α细胞以促进葡萄糖稳态。
J Biol Chem. 2016 Mar 25;291(13):6626-40. doi: 10.1074/jbc.M115.699504. Epub 2016 Jan 12.
8
Topical Intestinal Aminoimidazole Agonists of G-Protein-Coupled Bile Acid Receptor 1 Promote Glucagon Like Peptide-1 Secretion and Improve Glucose Tolerance.G蛋白偶联胆汁酸受体1的局部肠道氨基咪唑激动剂促进胰高血糖素样肽-1分泌并改善葡萄糖耐量。
J Med Chem. 2017 May 25;60(10):4185-4211. doi: 10.1021/acs.jmedchem.6b01873. Epub 2017 May 5.
9
Takeda G Protein-Coupled Receptor 5-Mechanistic Target of Rapamycin Complex 1 Signaling Contributes to the Increment of Glucagon-Like Peptide-1 Production after Roux-en-Y Gastric Bypass.武田 G 蛋白偶联受体 5-雷帕霉素复合物 1 信号通路促进 Roux-en-Y 胃旁路术后胰高血糖素样肽-1 的产生增加。
EBioMedicine. 2018 Jun;32:201-214. doi: 10.1016/j.ebiom.2018.05.026. Epub 2018 May 30.
10
Targeting the TGR5-GLP-1 pathway to combat type 2 diabetes and non-alcoholic fatty liver disease.靶向TGR5-GLP-1通路以对抗2型糖尿病和非酒精性脂肪性肝病。
Gastroenterol Clin Biol. 2010 Apr-May;34(4-5):270-3. doi: 10.1016/j.gcb.2010.03.009. Epub 2010 May 4.

引用本文的文献

1
Takeda G protein-coupled receptor 5 (TGR5): an attractive therapeutic target for aging-related cardiovascular diseases.武田G蛋白偶联受体5(TGR5):衰老相关心血管疾病的一个有吸引力的治疗靶点。
Front Pharmacol. 2025 Mar 20;16:1493662. doi: 10.3389/fphar.2025.1493662. eCollection 2025.
2
Machine learning and molecular dynamics simulations predict potential TGR5 agonists for type 2 diabetes treatment.机器学习和分子动力学模拟预测用于2型糖尿病治疗的潜在TGR5激动剂。
Front Chem. 2025 Jan 9;12:1503593. doi: 10.3389/fchem.2024.1503593. eCollection 2024.
3
The potential mechanism of action of gut flora and bile acids through the TGR5/TRPV1 signaling pathway in diabetic peripheral neuropathic pain.
肠道菌群和胆汁酸通过TGR5/TRPV1信号通路在糖尿病性周围神经病理性疼痛中的潜在作用机制
Front Endocrinol (Lausanne). 2024 Nov 15;15:1419160. doi: 10.3389/fendo.2024.1419160. eCollection 2024.
4
TGR5 receptors in SF1-expressing neurons of the ventromedial hypothalamus regulate glucose homeostasis.腹内侧下丘脑表达SF1的神经元中的TGR5受体调节葡萄糖稳态。
Mol Metab. 2025 Jan;91:102071. doi: 10.1016/j.molmet.2024.102071. Epub 2024 Nov 26.
5
Insights to the emerging potential of glucokinase activators as antidiabetic agent.揭示葡萄糖激酶激活剂作为抗糖尿病药物的新兴潜力。
Pharm Pat Anal. 2024;13(1-3):53-71. doi: 10.1080/20468954.2024.2389762. Epub 2024 Sep 11.
6
Gut-liver axis: Recent concepts in pathophysiology in alcohol-associated liver disease.肠-肝轴:酒精性肝病病理生理学的最新概念
Hepatology. 2024 Dec 1;80(6):1342-1371. doi: 10.1097/HEP.0000000000000924. Epub 2024 May 1.
7
Host-microbiome orchestration of the sulfated metabolome.宿主-微生物群对硫酸化代谢组的调控
Nat Chem Biol. 2024 Apr;20(4):410-421. doi: 10.1038/s41589-023-01526-9. Epub 2024 Feb 12.
8
Potential Therapeutic Targets for the Management of Diabetes Mellitus Type 2.2 型糖尿病管理的潜在治疗靶点。
Curr Med Chem. 2024;31(21):3167-3181. doi: 10.2174/0929867330666230501172557.
9
Emerging Roles of Gut Microbial Modulation of Bile Acid Composition in the Etiology of Cardiovascular Diseases.肠道微生物对胆汁酸组成的调节在心血管疾病发病机制中的新作用。
Nutrients. 2023 Apr 12;15(8):1850. doi: 10.3390/nu15081850.